• In the media
  • Novartis drops antibiotic development program
Media - published on 12 Jul 2018

Novartis drops antibiotic development program

Chris Dall of the Center for Infectious Disease Research and Policy (CIDRAP) quotes Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, on Novartis’ recent announcement to drop its antibacterial and antiviral research programs.

“Novartis leaving innovation in antibiotics is unfortunate, as we still need effective replacement antibiotics, and Novartis has a few in development. They are in discussions to divest them, so hopefully there’s a suitable partner to complete their development.” – Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation.


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.